Table 6.

Influence of different risk factors on time to post-transplant lymphoproliferative disorder development

	PTLD development ≤ 1 yr	PTLD development ≥ 1 yr	P value
All PTLD patients
Sex			0.150
Male	17	16
Female	14	6
Multi-organ involvement			0.007
(+)	15	3
(-)	14	18
CMV status			0.186
CMV-positive	9	4
CMV-negative	11	1
EBV status			0.296
EBV-positive	12	5
EBV-negative	8	1
Rejection episode			0.399
(+)	15	9
(-)	16	13
Mortality			0.324
(+)	13	7
(-)	18	15
Type of allograft			0.118
Living donor	19	9
Deceased donor	12	13
Pediatric PTLD patients
Sex			0.496
Male	15	8
Female	12	5
Multi-organ involvement			0.018
(+)	14	2
(-)	11	11
CMV status			0.368
CMV-positive	9	3
CMV-negative	9	1
EBV status			0.184
EBV-positive	12	5
EBV-negative	6	0
Rejection episode			0.587
(+)	13	6
(-)	14	7
Mortality			0.120
(+)	13	3
(-)	14	10
Type of allograft			0.609
Living donor	19	9
Deceased donor	8	4

CMV: Cytomegalovirus; EBV: Epstein-Barr virus; PTLD: Post-transplant lymphoproliferative disorder.